Literature DB >> 12372530

Substituted uracil derivatives as potent inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).

Henning Steinhagen1, Michael Gerisch, Joachim Mittendorf, Karl-Heinz Schlemmer, Barbara Albrecht.   

Abstract

A new class of PARP-1 inhibitors, namely substituted fused uracil derivatives were synthesised. Starting from a derivative with an IC(50)=2microM the chemical optimisation program led to compounds with more than a 100-fold increase in potency (IC(50)<20nM). Additionally, physicochemical and pharmacokinetic properties were evaluated. It could be shown that compounds bearing a piperazine or phenyl substituted betaAla-Gly side chain exhibited the best overall profile.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12372530     DOI: 10.1016/s0960-894x(02)00602-9

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

1.  Development of 1-(4-(Substituted)piperazin-1-yl)-2-((2-((4-methoxybenzyl)thio)pyrimidin-4-yl)oxy)ethanones That Target Poly (ADP-Ribose) Polymerase in Human Breast Cancer Cells.

Authors:  Suresha N Deveshegowda; Prashant K Metri; Rashmi Shivakumar; Ji-Rui Yang; Shobith Rangappa; Ananda Swamynayaka; Muthu K Shanmugam; Omantheswara Nagaraja; Mahendra Madegowda; Priya Babu Shubha; Arunachalam Chinnathambi; Sulaiman Ali Alharbi; Vijay Pandey; Kwang Seok Ahn; Peter E Lobie; Basappa Basappa
Journal:  Molecules       Date:  2022-04-29       Impact factor: 4.927

2.  Design, Synthesis and Molecular Modeling Study of Conjugates of ADP and Morpholino Nucleosides as A Novel Class of Inhibitors of PARP-1, PARP-2 and PARP-3.

Authors:  Yuliya V Sherstyuk; Nikita V Ivanisenko; Alexandra L Zakharenko; Maria V Sukhanova; Roman Y Peshkov; Ilia V Eltsov; Mikhail M Kutuzov; Tatjana A Kurgina; Ekaterina A Belousova; Vladimir A Ivanisenko; Olga I Lavrik; Vladimir N Silnikov; Tatyana V Abramova
Journal:  Int J Mol Sci       Date:  2019-12-27       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.